T1004	mode 218 227	ingestion
T1005	dosage 239 244	75 mg
T1006	drug 290 309	phenylpropanolamine
T1007	component 334 342	caffeine
T1008	dosage 419 424	75 mg
T1009	dosage 430 436	150 mg
T10010	dosage 442 447	75 mg
T10011	drug 448 451	PPA
T10012	dosage 457 463	400 mg
T10013	component 464 472	caffeine
T10014	dosage 474 480	400 mg
T10015	component 481 489	caffeine
T10016	studyType 561 603	double-blind, randomized, crossover design
T10019	mode 795 804	ingestion
T10021	dosage 869 875	150 mg
T10022	drug 876 879	PPA
T10024	dosage 890 895	75 mg
T10025	drug 896 899	PPA
T10026	dosage 905 911	400 mg
T10029	mode 953 962	ingestion
T10030	dosage 966 971	75 mg
T10031	drug 972 975	PPA
T10033	dosage 986 992	400 mg
T10034	component 993 1001	caffeine
T10037	dosage 1049 1055	150 mg
T10038	drug 1056 1059	PPA
T10039	value 1064 1089	173 +/- 9/103 +/- 4 mm Hg
T10043	dosage 1258 1264	150 mg
T10044	drug 1265 1268	PPA
T10047	drug 1459 1462	PPA
T10048	drug 1574 1577	PPA
T10050	drug 1830 1833	PPA
T10051	component 1851 1859	caffeine
T10052	meal 70 79	diet aids
T10054	drug 311 314	PPA
T10055	drug 425 428	PPA
T10056	drug 437 440	PPA
T10023	food 912 920	caffeine
T10036	interaction 821 830	increases
T10058	interaction 1299 1324	substantially elevates BP
T10061	pathology 1386 1422	nontraumatic intracranial hemorrhage
T10049	drug 1865 1868	PPA
T10045	dosage 249 261	double doses
T10063	meal 1288 1297	diet aids
T10064	drugClass 269 284	sympathomimetic
T2002	drug 50 69	phenylpropanolamine
T2003	studyType 111 145	placebo-controlled follow-up study
T20040	value 1105 1129	148 +/- 4/97 +/- 3 mm Hg
T20046	population 1426 1448	young, healthy persons
T20053	component 99 107	caffeine
T20057	population 507 540	16 resting, normotensive subjects
T2001	pathology 17 39	Transient hypertension
T20017	function 745 759	blood pressure
T20018	function 761 763	BP
T20020	function 818 820	BP
T20027	function 934 936	BP
T20035	function 1036 1038	BP
T20060	function 1193 1195	BP
T20042	value 1204 1229	137 +/- 8/85 +/- 5 mm Hg.
T20058	function 1322 1324	BP
T20065	studyType 1370 1382	case reports
T20066	dosage 1466 1506	recommended or minimally greater dosages
T1	interaction 922 946	Significant BP increases
R1	physiological_effect_potentiation Arg1:T10023 Arg2:T10025	
R2	physiological_effect_potentiation Arg1:T10034 Arg2:T10031	
